Amphastar Pharma (AMPH) Tops Q4 EPS by 12c, Slight Miss on Revenues

Amphastar Pharma (NASDAQ: AMPH) reported Q4 EPS of $0.10, $0.12 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $60.4 million versus the consensus estimate of $60.62 million.

Fourth Quarter Highlights

• Net revenues of $60.4 million for the fourth quarter
• GAAP net income of $1.5 million, or $0.03 per diluted share, for the fourth quarter
• Adjusted non-GAAP net income of $4.8 million, or $0.10 per diluted share, for the fourth quarter

For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.

You May Also Be Interested In

• Delta Air Lines (DAL) Tops Q2 EPS by 3c, Beats on Revenue; Offers Guidance
• Helen of Troy (HELE) Tops Q1 EPS by 22c, Beats on Revenue; Offers FY Guidance
• WD-40 Co. (WDFC) Tops Q3 EPS by 76c; offers guidance